BioAZ

BioAZ improves animal welfare and farmer benefit through biotechnology innovation

You can learn more about our company and our flagship project in this 3-minute video: https://youtu.be/Hx8ABG-YDGQ 

Our first innovation is a biodegradable alternative to pig castration, a major step forward for animal welfare. This product, painless for the animal, allows farmers to win 15 minutes and 5 to 6 euros per pig and addresses a worldwide market over €3 billion. Two other innovations are being developed: an alternative to castration for companion animals and an alternative to antibiotics for calves. 

An option-on-license agreement has been signed with a top 10 veterinary big pharma company in the world (undisclosed partner) for an amount of EUR 500,000+. In addition, BioAZ was the winner of the Pignnovation Award organized by MSD Animal Health, the 2nd largest global player in animal health with a turnover of USD 5.6 billion in 2023 (1st in Swine). This distinction was translated in an endowment of 75,000 USD for BioAZ. 

Co-founded in 2022 by Romain Delcombel, a veterinarian and expert in the development of biotechnologies for animal health, BioAZ relies on the expertise of veterinary and scientific senior team, consultants, and shareholders, including the group Cristal (the leading network of French rural veterinarians), as well as an internationally recognized advisory committee. We are actively working on the industrialization of our solution and are preparing the first clinical trials in pigs. 

Our objectives: to finalize the first phase of development, including the industrialization stages and clinical trials of our patented technology, adapted to dogs and pigs, before licensing to a major veterinary pharmaceutical company. To do this, we are raising €2 million (€ 610,000 already secured from historical investors and vets business angels) for 2 years to: 

• Finalizing the pig project’s R&D before licensing to a big pharma.
• Accelerating the development of our two other projects: a PoC for the dog project and a new patent for the calf project.

KPI summary:

• 3 R&D projects
• 2 laboratory PoC done
• 2 target-animal PoC done (pig and dog)
• 1 patent applied at EUIPO and extended in PCT procedure
• 1 option-to-license agreement signed

As an exit, we consider selling BioAZ in 4 to 5 years from now.